Monitor Phase 3 enrollment progress and BIM-DRS preliminary data expected in 2027; the AVS acquisition secures commercial manufacturing but adds integration risk. Cash runway through 2028 provides ample time to reach data milestones.
Drug in focus
SGP drug pipeline →Bimatoprost Drug Pad-IOL System
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- Phase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.
- Next catalyst
- None dated
What to watchWatch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.
Price Chart
Executive Summary
SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73/share), wider than the $9.8M loss in Q3 2025, driven by increased R&D and G&A spending. The company highlighted positive clinical milestones: four-year BIM-IOL System follow-up data showing 86% of patients off topical drops, completion of first BIM-DRS implantations, and the $13M acquisition of IOL manufacturer AVS. Cash of $215.8M is expected to fund operations through 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $24.3M versus $9.8M in Q3 2025
- Cash, cash equivalents and short-term investments of $215.8M as of September 30, 2026
- Acquired Advanced Vision Science, Inc. for approximately $13M in cash
- Four-year BIM-IOL System FIH data: 86% of patients off topical drops, 37% mean IOP reduction
- First implantations completed in BIM-DRS FIH trial
- Phase 3 enrollment on track for completion in 2027
- R&D expenses $10.0M (Q3 2026) vs $8.1M (Q3 2025)
- G&A expenses $16.2M (Q3 2026) vs $3.0M (Q3 2025)
Financial Impact
Net loss widened by $14.5M year-over-year to $24.3M; cash burn rate increased to ~$28.5M per quarter (from $9.8M net loss in Q3 2025 plus acquisition spend)
Risk Factors
- Pre-revenue stage with widening net losses and no approved products
- Phase 3 trial results and regulatory approval for BIM-IOL System are uncertain
- BIM-DRS is in early clinical stage with no efficacy data yet
- Acquisition integration costs and manufacturing scale-up execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001778922-26-000055 |
| Document: sgp-20261111.htm | 0001778922-26-000055 |
| Document: 0001778922-26-000055-index-headers.html | 0001778922-26-000055 |
| Document: 0001778922-26-000055-index.html | 0001778922-26-000055 |
| Document: 0001778922-26-000055.txt | 0001778922-26-000055 |
| 8-K Data (Synthetic) | 0001778922-26-000055 |
Track record
9 reports on SGP
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing No price data
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
- Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- May 14, 202626w ago 8-K Neutral 4/10 Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
- Mar 26, 202633w ago Press Release Bullish 8/10 Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
- Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers